RCUS · Arcus Biosciences, Inc.
$18.54
-4.24% last session
End-of-day data · close of 2026-10-23
Market cap
$2B
Enterprise value
$2B
Trailing P/E
—
Forward P/E
-5.9
Dividend yield
0.0%
Beta
0.94
Avg volume
2M
Employees
1K
Daily Change %
-4.24%
5 Days Change
-12.48%
10 Days Change
-13.99%
30 Days Change
-26.64%
60 Days Change
-35.72%
Month to Day Change
-23.27%
Year to Day Change
-18.76%
Analyst Outlook
Analyst estimates change daily — follow the shifts on the Estimate Trends page.
Technical Analysis
Analyst sentiment over time — RCUS
Rec Mean (blue, left — higher = more bullish) vs. price targets (right).
Investment Bank Ratings as of 2026-10-21
Latest call per bank · past 12 months
Citigroup
Buy$50.00
+169.7% vs priceJP Morgan
Overweight$41.00
+121.1% vs priceWells Fargo
Equal-Weight$26.00
+40.2% vs priceMorgan Stanley
Equal-Weight$22.00
+18.7% vs priceGoldman Sachs
Buy$34.00
+83.4% vs priceBank of America
Neutral$26.00
+40.2% vs priceRecent rating actions
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-21 | Citigroup | Maintains | Buy | $45.00 → $50.00 |
| 2026-10-21 | Truist Securities | Maintains | Buy | $40.00 → $41.00 |
| 2026-10-21 | Wedbush | Maintains | Outperform | $43.00 → $49.00 |
| 2026-10-16 | William Blair | Initiates | Outperform | $0.00 |
| 2026-10-14 | JP Morgan | Initiates | Overweight | $0.00 → $41.00 |
| 2026-09-30 | Wedbush | Reiterates | Outperform | $43.00 |
| 2026-09-16 | TD Cowen | Initiates | Buy | $0.00 |
| 2026-09-08 | Truist Securities | Reiterates | Buy | $35.00 → $40.00 |
Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.
Signal Summary as of 2026-10-23
- bullish: RSI (14): RSI is 28 — oversold territory; selling pressure looks stretched.
- bearish: Price vs 50-day MA: Trading 29.0% below the 50-day MA ($26.12).
- bearish: Price vs 200-day MA: Trading 25.1% below the 200-day MA ($24.76).
- bullish: MA cross: The 50-day MA sits above the 200-day MA (golden-cross regime) — the longer-term trend points up.
- bearish: MACD (12,26,9): MACD histogram is negative (-0.41) — short-term momentum is fading.
- neutral: 52-week range: Price sits between the 52-week low ($16.78) and high ($31.57).
RCUS Price Chart
Loading chart for RCUS…
Fundamentals
About Arcus Biosciences, Inc.
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's development product portfolio includes Casdatifan, a HIF-2a inhibitor for the treatment of kidney cancer; Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial for lung and gastrointestinal cancers; and Zimberelimab, an anti-PD-1 antibody. It also develops Quemliclustat, a small molecule inhibitor that targets the CD73 enzyme in the ATP-adenosine pathway, which is in phase 3 and phase 1/1b clinical trial for lung and pancreatic cancer. In addition, the company develops AB598, a CD39 antibody, which is in phase 1/1b clinical study for gastrointestinal cancer and AB801, an AXL inhibitor, which is in Phase 1b clinical trial for lung cancer. It has clinical collaboration with AstraZeneca for the Phase 3 PACIFIC-8 trial evaluating domvanalimab and durvalumab in Stage 3 NSCLC and for a Phase 1/1b study evaluating casdatifan and volrustomig in IO-naive patients with ccRCC; BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases; and Bristol-Myers Squibb Company to develop a novel treatment regimen that delivers tumor control in kidney cancer. Arcus Biosciences, Inc. was incorporated in 2015 and is based in Hayward, California.
More in Biotechnology
VRTX
Vertex Pharmaceuticals Incorpor
$133B 18.1% YTD
REGN
Regeneron Pharmaceuticals, Inc.
$83B 6.5% YTD
MRNA
Moderna, Inc.
$80B 587.1% YTD
ARGX
argenx SE
$55B 4.1% YTD
ONC
BeOne Medicines Ltd.
$43B 25.8% YTD
RVMD
Revolution Medicines, Inc.
$40B 135.6% YTD
RPRX
Royalty Pharma plc
$37B 67.3% YTD
ALNY
Alnylam Pharmaceuticals, Inc.
$30B -42.8% YTD
Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.